Abstract:

Breast cancer is the most frequently diagnosed type of cancer and the foremost reason of the death of women from cancer. Hormone receptor positive breast cancer is the most frequent type of breast cancer. Anastrosole is one of the aromatase inhibitors which is indicated for early stage of hormone receptor positive breast cancer of postmenopausal women. A 67-year-old woman was refered to Rheumatology Department from Medical Oncology Department for skin rashes which have started 3 months ago. In her medical history, she was diagnosed as infiltrative ductal carcinoma grade-2 in the right breast. She had a modified radical mastectomy operation for the right breast and subsequently, anastrosole was started as her hormone receptor was found positive in histopathological examination. The drug was stopped after 5 years by her oncologist however she went on using the drug on her own demand. Three months before her referral, non-itchy, painless reddish rash was started on legs and arms. After careful physical and laboratory examination and histopathologic alevaluation, she was diagnosed as middle-vessel necrotising vasculitis. Anastrosole was stopped. Steroid and azathyoprine were started. On the fifth month of therapy, all skin lesions were resolved with postinflammatory hyperpigmentation. No additional problem was met. This case report is suggesting that, anastrosole which is a frequently preferred agent in recentyears, could also cause leucocytoclastic vasculits. Very rare cases with cutanous vasculitis were previously presented. This case report suggests that, during the management of patients under anastrosole therapy, cutanous vasculitis should be monitored carefully.

Keywords: